Literature DB >> 20300976

Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.

Fang Zhu1, Zhe Zhang, Gang Wu, Zhenyu Li, Ruiguang Zhang, Jinghua Ren, Li Nong.   

Abstract

Rho and Rho-associated kinase play an important role in focal adhesion, stress fiber formation and cell motility. Fasudil is a kind of Rho kinase inhibitor. The effect and precise molecular mechanism of fasudil on the biology behavior of lung cancer cell A549 remains unclear. The cytotoxic effect of fasudil on A549 cell was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Wound-healing assay was used to evaluate the effect of fasudil on migration activity of A549 cells. The invasion activity of A549 cells was detected by transwell chamber assay. The expression of MMPs was measured by gelatin zymography. RT-PCR and western blot were used to investigate the molecular change of A549 cells after treated with fasudil. Fasudil-inhibited proliferation of A549 cells in a concentration-dependent manner, decreased the migration and invasion activity. After treated with fasudil, the expression of MMP-2 and MMP-9 was significantly inhibited compared with the control group. Furthermore, the expression of RhoA and VEGF of A549 cell treated with fasudil was significantly down-regulated. Our findings indicate that fasudil might have a therapeutic potential for lung cancer though inhibiting cell proliferation, migration, invasion, MMPs activity and down-regulating the expression of RhoA and VEGF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300976     DOI: 10.1007/s12032-010-9468-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

1.  Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).

Authors:  Eckart Laack; Antje Scheffler; Iris Burkholder; Ina Boeters; Birte Andritzky; Gunter Schuch; Michael Görn; Gaby Vohwinkel; Lutz Edler; Walter Fiedler; Dieter Kurt Hossfeld
Journal:  Lung Cancer       Date:  2005-10       Impact factor: 5.705

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

3.  Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension.

Authors:  K Gohji; N Fujimoto; I Hara; A Fujii; A Gotoh; H Okada; S Arakawa; S Kitazawa; H Miyake; S Kamidono; M Nakajima
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

4.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

5.  Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage.

Authors:  E Tachibana; T Harada; M Shibuya; K Saito; M Takayasu; Y Suzuki; J Yoshida
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

6.  Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters.

Authors:  Hai-bo Wang; Xiang-ping Liu; Jun Liang; Kun Yang; Ai-hua Sui; Yan-jun Liu
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

7.  Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour.

Authors:  T Kamai; K Arai; T Tsujii; M Honda; K Yoshida
Journal:  BJU Int       Date:  2001-02       Impact factor: 5.588

Review 8.  MMP-2: expression, activation and inhibition.

Authors:  M L Corcoran; R E Hewitt; D E Kleiner; W G Stetler-Stevenson
Journal:  Enzyme Protein       Date:  1996

Review 9.  The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.

Authors:  Yasuharu Sasaki; Masaaki Suzuki; Hiroyoshi Hidaka
Journal:  Pharmacol Ther       Date:  2002 Feb-Mar       Impact factor: 12.310

10.  Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters.

Authors:  G Fritz; C Brachetti; F Bahlmann; M Schmidt; B Kaina
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more
  24 in total

1.  Comparison of the effect of intravitreal bevacizumab and intravitreal fasudil on retinal VEGF, TNFα, and caspase 3 levels in an experimental diabetes model.

Authors:  Fatih Celik; Fatih Ulaş; Zeynep Güneş Ozünal; Tülin Fırat; Serdal Celebi; Umit Doğan
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

2.  Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.

Authors:  Sujatha Iyengar; Caixin Zhan; Jordan Lu; Robert Korngold; David H Schwartz
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-02       Impact factor: 5.742

Review 3.  The Unwanted Cell Migration in the Brain: Glioma Metastasis.

Authors:  Xue Tao Qi; Jiang Shan Zhan; Li Ming Xiao; Lina Li; Han Xiao Xu; Zi Bing Fu; Yan Hao Zhang; Jing Zhang; Xi Hua Jia; Guo Ge; Rui Chao Chai; Kai Gao; Albert Cheung Hoi Yu
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

4.  Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.

Authors:  Ajaya Kumar Reka; Rork Kuick; Himabindu Kurapati; Theodore J Standiford; Gilbert S Omenn; Venkateshwar G Keshamouni
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

5.  Increased activity of Rho kinase contributes to hemoglobin-induced early disruption of the blood-brain barrier in vivo after the occurrence of intracerebral hemorrhage.

Authors:  Zhenghao Fu; Yizhao Chen; Fengzhen Qin; Shuo Yang; Xinqing Deng; Rui Ding; Liang Feng; Weiguang Li; Jianfeng Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 6.  Targeting the cytoskeleton against metastatic dissemination.

Authors:  Carmen Ruggiero; Enzo Lalli
Journal:  Cancer Metastasis Rev       Date:  2021-01-20       Impact factor: 9.264

7.  Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis.

Authors:  Haimei Qin; Rong Wang; Guijiang Wei; Huaifei Wang; Guogang Pan; Rentong Hu; Yesheng Wei; Renguang Tang; Junli Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-06       Impact factor: 2.503

8.  Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients.

Authors:  Minghui Li; Yong Cai; Hongmei Zhao; Zongyuan Xu; Qingsong Sun; Man Luo; Lizhi Gu; Min Meng; Xiang Han; Hong Sun
Journal:  Tumour Biol       Date:  2015-02-03

9.  In vivo expression and regulation of genes associated with vascularization during early response of sutures to tensile force.

Authors:  Nobuo Takeshita; Masakazu Hasegawa; Kiyo Sasaki; Daisuke Seki; Masahiro Seiryu; Shunro Miyashita; Ikuko Takano; Toshihito Oyanagi; Yuki Miyajima; Teruko Takano-Yamamoto
Journal:  J Bone Miner Metab       Date:  2016-01-29       Impact factor: 2.626

10.  Differential Contributions of Actin and Myosin to the Physical Phenotypes and Invasion of Pancreatic Cancer Cells.

Authors:  Angelyn V Nguyen; Brittany Trompetto; Xing Haw Marvin Tan; Michael B Scott; Kenneth Hsueh-Heng Hu; Eric Deeds; Manish J Butte; Pei Yu Chiou; Amy C Rowat
Journal:  Cell Mol Bioeng       Date:  2019-10-31       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.